Literature DB >> 22326632

Keratinocyte dysplasia in hematopoietic stem cell transplantation recipients in the day-28-to-84 posttransplantation period.

Ning Li1, Katherine A Guthrie, Barry E Storer, Paul J Martin, George E Sale, Zsolt B Argenyi, David Myerson.   

Abstract

Severe keratinocyte dysplasia (SKD) has been reported as a common event in the early posttransplantation period of hematopoietic stem cell transplantation patients. The purpose of our study is to determine the possible causes of SKD during the intermediate posttransplantation period and to ascertain its prevalence in skin biopsies. Skin biopsy slides, obtained from hematopoietic stem cell transplantation recipients who were days 28 to 84 posttransplantation, were evaluated for SKD. Forty-four examples of SKD were identified in 467 slides, or 9%. Thirty-seven patients were evaluated as cases in a case-control design. SKD was strongly associated with a conditioning regimen containing busulfan with an odds ratio of 7.25 (P = .0002). In a multivariate-adjusted analysis, SKD was not associated with cyclophosphamide, fludarabine, total-body irradiation, or a nonmyeloablative conditioning regimen. SKD was not associated with clinical acute graft-versus-host disease. SKD histology gradually resolved, reaching a normal histology after an average of 241 days. This study finds that severe keratinocyte dysplasia in the period 28 to 84 days post-HSCT is strongly associated with a busulfan-conditioning regimen.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326632      PMCID: PMC3402699          DOI: 10.1016/j.bbmt.2012.02.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

Review 1.  Chemotherapy and keratinocytes.

Authors:  Lance B Henry; Thomas D Horn
Journal:  J Cutan Pathol       Date:  2002-11       Impact factor: 1.587

2.  Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease.

Authors:  S Kohler; M R Hendrickson; N J Chao; B R Smoller
Journal:  Am J Surg Pathol       Date:  1997-09       Impact factor: 6.394

3.  Subacute radiation dermatitis: a histologic imitator of acute cutaneous graft-versus-host disease.

Authors:  P E LeBoit
Journal:  J Am Acad Dermatol       Date:  1989-02       Impact factor: 11.527

4.  The skin biopsy in the diagnosis of acute graft-versus-host disease in man.

Authors:  G E Sale; K G Lerner; E A Barker; H M Shulman; E D Thomas
Journal:  Am J Pathol       Date:  1977-12       Impact factor: 4.307

Review 5.  The cutaneous histopathology of chemotherapeutic reactions.

Authors:  J E Fitzpatrick
Journal:  J Cutan Pathol       Date:  1993-02       Impact factor: 1.587

6.  Cutaneous busulfan effect in patients receiving bone-marrow transplantation.

Authors:  S R Hymes; S C Simonton; E R Farmer; W B Beschorner; P J Tutschka; G W Santos
Journal:  J Cutan Pathol       Date:  1985-04       Impact factor: 1.587

Review 7.  Pathology and recent pathogenetic studies in human graft-versus-host disease.

Authors:  G E Sale
Journal:  Surv Synth Pathol Res       Date:  1984

8.  Keratinocyte dysplasia: an usual finding after transplantation or chemotherapy.

Authors:  Esther Castaño; Jose Luis Rodríguez-Peralto; Fernando López-Ríos; Carlos Gómez; Marta Zimmermann; Luis Iglesias Díez
Journal:  J Cutan Pathol       Date:  2002-11       Impact factor: 1.587

9.  Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.

Authors:  P J Martin; B J Nelson; F R Appelbaum; C Anasetti; H J Deeg; J A Hansen; G B McDonald; R A Nash; K M Sullivan; R P Witherspoon; P J Scannon; N Friedmann; R Storb
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

Review 10.  Acute cutaneous eruptions after marrow ablation: roses by other names?

Authors:  T D Horn
Journal:  J Cutan Pathol       Date:  1994-10       Impact factor: 1.587

View more
  3 in total

1.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

2.  Autologous GVHD?

Authors:  F Otegbeye; R P Gale; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

3.  Incidence, Histopathological Features and Differential Diagnosis of Cutaneous Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation.

Authors:  Uguray Payam Hacisalihoglu; Davut Sahin
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.